Optimal Duration of Dual Antiplatelet Therapy after Stent- Assisted Coil Embolization of Unruptured Intracranial Aneurysms : A Prospective Randomized Multicenter Trial
- Author:
Seung Pil BAN
1
;
O-Ki KWON
;
Young Deok KIM
;
Bum-Tae KIM
;
Jae Sang OH
;
Kang Min KIM
;
Chang Hyeun KIM
;
Chang-Hyun KIM
;
Jai Ho CHOI
;
Young Woo KIM
;
Yong Cheol LIM
;
Hyoung Soo BYOUN
;
Sukh Que PARK
;
Joonho CHUNG
;
Keun Young PARK
;
Jung Cheol PARK
;
Hyon-Jo KWON
;
Author Information
- Publication Type:Special Article
- From:Journal of Korean Neurosurgical Society 2022;65(6):765-771
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:: Stent-assisted coil embolization (SAC) has been increasingly used to treat various types of intracranial aneurysms. Delayed thromboembolic complications are major concerns regarding this procedure, so dual antiplatelet therapy with aspirin and clopidogrel is needed. However, clinicians vary the duration of dual antiplatelet therapy after SAC, and no randomized study has been performed. This study aims to compare the safety and efficacy of long-term (12 months) dual antiplatelet therapy and shortterm dual antiplatelet therapy (6 months) after SAC for patients with unruptured intracranial aneurysms (UIAs).
Methods:: This is a prospective, randomized and multicenter trial to investigate the optimal duration of dual antiplatelet therapy after SAC in patients with UIAs. Subjects will receive dual antiplatelet therapy for 6 months (short-term group) or 12 months (longterm group) after SAC. The primary endpoint is the assessment of thromboembolic complications between 1 and 18 months after SAC. We will enroll 528 subjects (264 subjects in each group) and perform 1 : 1 randomization. This study will involve 14 topperforming, high-volume Korean institutions specializing in coil embolization.
Results:: The trial will begin enrollment in 2022, and clinical data will be available after enrollment and follow-up.
Conclusion:: This article describes that the aim of this prospective randomized multicenter trial is to compare the effect of short-term (6 months) and long-term (12 months) dual antiplatelet therapy on UIAs in patients undergoing SAC, and to find the optimal duration.
